Sander Van Deventer

Dr. Sander van Deventer is a physician-scientist, drug developer, and venture capitalist, recognized for paradigm-shifting contributions to modern medicine and biotechnology. Scientific and Drug Development Achievements: • Remicade (infliximab): Played a critical role in the development of Remicade, the first commercial monoclonal antibody for autoimmune diseases, fundamentally changing the treatment of Crohn’s disease, rheumatoid arthritis, and related conditions. • Glybera : Co-founded Amsterdam Molecular Therapeutics (now uniQure), leading the development of Glybera, the first gene therapy to receive market authorization in the Western world, marking a breakthrough for gene therapy as a clinical and commercial reality. • Hemgenix and AMT-130 : Drove the development of Hemgenix (AAV5-FIX) for hemophilia B, which achieved FDA priority review and market authorization, representing a major advance in gene therapy for rare diseases. Designed and developed AMT-130, which is in late-stage